Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. First Internet Bancorp

23.7% sales growth and 8.3% return on equity

First Internet Bancorp operates as the bank holding company for First Internet Bank of Indiana that provides commercial and retail banking products and services in the United States.

First Internet Bancorp sales growth this year is expected to be 10.6% and 23% for next year.

Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 83.58M for the twelve trailing months.

First Internet Bancorp’s sales growth for the next quarter is 23.7%. The company’s growth estimates for the present quarter and the next is 15.3% and 21%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.3%.

First Internet Bancorp’s Stock Top and Bottom Yearly Value

First Internet Bancorp’s stock is valued at $27.41 at 12:51 EST, below its 52-week high of $28.50 and way above its 52-week low of $10.47.

First Internet Bancorp’s Moving Average

First Internet Bancorp’s value is way higher than its 50-day moving average of $23.73 and way higher than its 200-day moving average of $17.77.

2. The Bank of Princeton

21.6% sales growth and 6.57% return on equity

The Bank of Princeton provides various banking products and services. The company accepts checking, savings, attorney trust, and money market accounts, as well as certificates of deposit.

The Bank of Princeton sales growth this year is expected to be 17.6% and 1.9% for next year.

Year-on-year quarterly revenue growth grew by 3.5%, now sitting on 46.43M for the twelve trailing months.

The Bank of Princeton’s sales growth for the next quarter is 21.6%. The company’s growth estimates for the ongoing quarter and the next is 14.3% and 9.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.57%.

The Bank of Princeton’s Stock Top and Bottom Yearly Value

The Bank of Princeton’s stock is valued at $24.80 at 12:51 EST, way under its 52-week high of $32.25 and way above its 52-week low of $17.40.

The Bank of Princeton’s Moving Average

The Bank of Princeton’s worth is way higher than its 50-day moving average of $21.71 and way higher than its 200-day moving average of $19.91.

3. West Pharmaceutical Services, Inc.

15.6% sales growth and 19.44% return on equity

West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally.

West Pharmaceutical Services, Inc. sales growth this year is expected to be 14.9% and 11.1% for next year.

Year-on-year quarterly revenue growth grew by 20.1%, now sitting on 2.04B for the twelve trailing months.

West Pharmaceutical Services, Inc.’s sales growth for the next quarter is 15.6%. The company’s growth estimates for the ongoing quarter and the next is 36.6% and 18.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.44%.

West Pharmaceutical Services, Inc.’s Stock Top and Bottom Yearly Value

West Pharmaceutical Services, Inc.’s stock is valued at $272.24 at 12:51 EST, way below its 52-week high of $305.00 and way above its 52-week low of $124.53.

West Pharmaceutical Services, Inc.’s Moving Average

West Pharmaceutical Services, Inc.’s value is below its 50-day moving average of $282.40 and above its 200-day moving average of $259.02.

4. ServiceNow

24.3% sales growth and 34.15% return on equity

ServiceNow, Inc. provides enterprise cloud computing solutions that defines, structures, consolidates, manages, and automates services for enterprises worldwide.

ServiceNow sales growth this year is anticipated to be 29.7% and 24.9% for next year.

Year-on-year quarterly revenue growth grew by 30%, now sitting on 4.22B for the twelve trailing months.

ServiceNow’s sales growth for the next quarter is 24.3%. The company’s growth estimates for the present quarter and the next is 10.4% and 21%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.15%.

ServiceNow’s Stock Top and Bottom Yearly Value

ServiceNow’s stock is valued at $525.70 at 12:51 EST, below its 52-week high of $541.74 and way higher than its 52-week low of $238.93.

ServiceNow’s Moving Average

ServiceNow’s worth is higher than its 50-day moving average of $511.83 and way higher than its 200-day moving average of $454.42.

5. K12 Inc

42.8% sales growth and 6.98% return on equity

K12 Inc., a technology-based education company, provides proprietary and third-party online curriculum, software systems, and educational services to facilitate individualized learning for students primarily in kindergarten through 12th grade (K-12) in the United States and internationally.

K12 Inc sales growth this year is anticipated to be 41.9% and a negative 1.3% for next year.

Year-on-year quarterly revenue growth grew by 44.3%, now sitting on 1.15B for the twelve trailing months.

K12 Inc’s sales growth for the next quarter is 42.8%. The company’s growth estimates for the current quarter and the next is a negative 5.8% and 40.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.98%.

K12 Inc’s Stock Top and Bottom Yearly Value

K12 Inc’s stock is valued at $22.23 at 12:51 EST, way below its 52-week high of $52.84 and way higher than its 52-week low of $15.06.

K12 Inc’s Moving Average

K12 Inc’s value is way under its 50-day moving average of $25.36 and way below its 200-day moving average of $31.75.

6. Halozyme Therapeutics, Inc.

281.6% sales growth and 12.5% return on equity

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally.

Halozyme Therapeutics, Inc. sales growth this year is expected to be 35% and 56.5% for next year.

Year-on-year quarterly revenue growth grew by 41.3%, now sitting on 199.56M for the twelve trailing months.

Halozyme Therapeutics, Inc.’s sales growth for the next quarter is 281.6%. The company’s growth estimates for the ongoing quarter and the next is 316.7% and 1025%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.5%.

Halozyme Therapeutics, Inc.’s Stock Top and Bottom Yearly Value

Halozyme Therapeutics, Inc.’s stock is valued at $40.12 at 12:51 EST, under its 52-week high of $41.55 and way above its 52-week low of $12.71.

Halozyme Therapeutics, Inc.’s Moving Average

Halozyme Therapeutics, Inc.’s worth is way higher than its 50-day moving average of $35.10 and way above its 200-day moving average of $28.82.

LEAVE A REPLY

Please enter your comment!
Please enter your name here